Juba 261 inimeseni on jõudnud selle ettevõtte bränding aga tema tegevusi ei jälgi ükski kasutaja. Keskmiselt on ettevõtet hinnatud 2,5 punktiga aga kommenteeritud ei ole.

Tegevusaruanne 2024

Management Report

The company started preparing a business plan in early 2019.

2024 Outlook:

Due to the logistical problems caused by the Russian-Ukrainian war and the economic challenges worldwide in addition to the political disturbances in the middle east, suppliers and manufacturing partners such as Greece, Spain are still pending.

The products we offer are haemostatics, blood bags and dietary supplements. Our goal is still to register and sell these products in the EU and the Middle East.

Plan for 2025:

In 2025, our goal is to complete the transactions with our manufacturing partners, appoint some agents in the ME and register at least one hemostatic product in the Middle East.